Complete report $9,600. DataPack (test volumes, sales forecasts, supplier shares) $6,200.
“New Frontiers in the U.S. Coagulation Testing Market: Business Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group’s new report designed to help current suppliers and potential market entrants identify and evaluate emerging business opportunities and develop effective strategies for the U.S. coagulation testing market during the next five years.
The report explores business and technological trends in the U.S. coagulation testing market; provides estimates of the test volume, as well as sales and market shares for leading instrument and reagent competitors; compares features of major analyzers; profiles leading market players; analyzes potential applications of emerging technologies; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years. Rationale The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromogenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, computers and laboratory automation will radically change the U.S. coagulation diagnostics practice during the next five years. New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating additional opportunities and challenges for suppliers.
U.S. Market Overview
- Comprehensive market segmentation analysis, including review
of the market dynamics, structure, size, growth and major suppliers.
- Estimated universe of facilities performing coagulation tests.
- Five-year test volume and sales projections.
Business Opportunities and Strategic Recommendations
- Product development and business expansion
opportunities with significant market appeal.
- “Ideal” product models with tentative
prices and operating characteristics.
- Alternative market penetration
strategies for instrument and reagent suppliers.
- Potential market entry barriers and risks.
Current and Emerging Coagulation Tests
Activated Clotting Time (ACT) (1), Activated Protein C Resistance,
Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time,
D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX,
Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII,
Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation,
Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Plasmin, Plasminogen,
Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S,
Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time,
Von Willebrand's Factor Fav/Ag, and others.
Sales and Market Share Analysis of Instrument and Reagent Suppliers
- Sales and market shares of major instrument
and consumable manufactures.
Market Segmentation Analysis
- Comprehensive market
segmentation analysis, including:
- Commercial/Private Laboratories
- Physician Offices
- Test volume forecasts for over 40 major procedures,
by market segment.
Current and Emerging Products
- Review of established and new procedures.
- Comparison of automated and semi-automated
analyzers marketed by Diagnostica Stago, Helena, IL,
Roche, Siemens, Sysmex and other suppliers.
- Analysis of current and emerging technologies
and their potential market applications.
- Comprehensive lists of companies developing
or marketing new technologies and products by test.
- Strategic assessments of major suppliers and start-up firms
developing innovative coagulation testing technologies
and products, including their sales, product portfolios,
marketing tactics, collaborative arrangements, and new products in R&D.
- The companies analyzed in the report include:
- ADI/American Diagnostica
- Beckman Coulter/Danaher
- Becton Dickinson
- Corgenix Medical
- Diagnostica Stago/Trinity Biotech
- Helena Laboratories
- Hyphen BioMed
- Instrumentation Laboratory
- ITC/Nexus Dx
- Thermo Fisher
Contains 424 pages and 37 tables